Nexalin Technology
Nexalin Technology is a Houston-based, NASDAQ-listed medical device company developing non-invasive transcranial neurostimulation devices (Gen-2 SYNC and Gen-3 HALO Clarity) using its proprietary DIFS platform to treat anxiety, depression, insomnia, and related neurological conditions through subscription and device sales.
- Company typePublic
- Founded2010
- HeadquartersHouston, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Nexalin Technology does
Nexalin Technology is a Houston-based, NASDAQ-listed (NXL) medical device company founded in 2010 that develops non-invasive transcranial electrical stimulation equipment for the treatment of anxiety, depression, insomnia, and related neurological conditions. Its core technology is the proprietary DIFS (Deep Intracranial Frequency Stimulation) platform, which delivers a 15 mA, 77.5 Hz alternating current waveform designed to interact with deep midbrain structures and normalize brain neurochemistry without medication. The product portfolio consists of the Gen-2 SYNC clinical console, which has received regulatory approvals in China, Brazil, Oman, and Israel, and the Gen-3 HALO Clarity headset, a home-use device currently in a 160-participant pivotal FDA trial targeting moderate-to-severe insomnia via the De Novo pathway.
The company monetizes through three streams: one-time device sales of Gen-2 SYNC hardware in approved international markets, an exclusive distribution partnership with Carmi Masha Technologies in Israel, and a subscription-based virtual clinic model delivered via the AI-designed NeuroCare platform integrated with the recently acquired PONM digital health system. Reported clinical outcomes from trials conducted at the University of São Paulo include a 77.8% anxiety response rate and 66.7% depression response/remission rate, and a U.S. Patent (No. 12,629,519) provides intellectual property protection through 2042.
Nexalin is at an early commercialization stage: it employs 1-10 people, reports approximately $280,000 in LTM revenue as of June 2026, and has raised roughly $11.5 million since 2024 through two underwritten public offerings (Maxim Group LLC) plus a $1.3 million stock-funded acquisition of PONM, Inc. The company's strategic priorities are advancing HALO Clarity through FDA clearance, expanding the NeuroCare virtual clinic subscription model, and pursuing adjacent indications including Alzheimer's disease, TBI, and PTSD via academic and VA clinical partnerships.
Nexalin Technology firmographics
Firmographics- Name
- Nexalin Technology
- Legal name
- Nexalin Technology Inc
- Website
- https://nexalin.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nexalin Technology is a Houston-based, NASDAQ-listed medical device company developing non-invasive transcranial neurostimulation devices (Gen-2 SYNC and Gen-3 HALO Clarity) using its proprietary DIFS platform to treat anxiety, depression, insomnia, and related neurological conditions through subscription and device sales.
- Ownership category
- akta.pro rank
Nexalin Technology industry classification
Industry- Product category
- Neurostimulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industries
- General Neurology (HLAKAIAA), Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)
Keywords
Where Nexalin Technology is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Nexalin Technology business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Virtual Clinic Subscription: Subscription-based business model through NeuroCare virtual clinic platform. Patients pay for ongoing neurostimulation treatments administered at home under physician supervision. Designed for scalable, recurring revenue from global brain health markets.
- Device Sales: Direct sales of Gen-2 SYNC neurostimulation devices in approved international markets (China, Brazil, Oman, Israel). One-time device purchases supplemented by ongoing treatment delivery.
- Distribution/ Licensing: Revenue through exclusive distribution agreements with regional partners like Carmi Masha Technologies Ltd. in Israel. Company provides products while distributors handle local commercialization.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels3 records
Nexalin Technology product offering
Product offeringCore offering
Nexalin Technology develops and commercializes non-invasive transcranial neurostimulation devices based on its proprietary Deep Intracranial Frequency Stimulation (DIFS) platform, delivering 15 mA, 77.5 Hz frequency-based waveforms to treat anxiety, depression, insomnia, traumatic brain injury, PTSD, and Alzheimer's disease. The company sells its Gen-2 SYNC devices in approved international markets and operates an AI-powered NeuroCare virtual clinic platform that enables physicians to remotely prescribe and monitor home-based neurostimulation treatments.
Product overview
Nexalin Technology offers a unified neurostimulation platform centered on its proprietary DIFS™ (Deep Intracranial Frequency Stimulation) technology. The product portfolio consists of Gen-2 SYNC and Gen-3 HALO Clarity neurostimulation devices that deliver the DIFS waveform for mental health treatment, supported by the AI-designed NeuroCare virtual clinic platform for remote patient monitoring and care management. The recently acquired PONM digital health platform integrates with HALO Clarity and NeuroCare to provide remote patient monitoring, clinical data capture, EHR functionality, and virtual clinic management. The Gen-2 SYNC device has regulatory approvals in China, Brazil, Oman, and Israel, while Gen-3 HALO Clarity is advancing through FDA De Novo regulatory pathway for insomnia treatment in the US.
Differentiator
Problem solved
Functional benefit
Brands
- HALO Clarity: Gen-3 HALO neurostimulation headset for treating insomnia and other brain health conditions using Deep Intracranial Frequency Stimulation technology
- NeuroCare
- DIFS
- Gen-2 SYNC
Products and services
- DIFS (Deep Intracranial Frequency Stimulation) Platform Core neurostimulation technology platform using 15 mA, 77.5 Hz frequency-based waveforms that interact with deep centers of the midbrain to normalize brain neurochemicals for treatment of anxiety, depression, insomnia, and other neurological conditions. Sold as the technological foundation underlying Nexalin's hardware devices.
- Gen-2 SYNC Neurostimulation Device Second-generation medical device delivering DIFS technology, designed for clinical setting use to treat mental health conditions including depression and insomnia. Regulatory approved in China, Brazil, Oman, and Israel.
- Gen-3 HALO Clarity Headset Third-generation non-invasive home-use headset for delivering DIFS neurostimulation treatment under physician supervision, integrated with the NeuroCare virtual clinic platform for remote patient monitoring. Advancing through FDA De Novo regulatory pathway for insomnia treatment in the US.
- NeuroCare Virtual Clinic AI-designed subscription-based virtual clinic platform enabling remote physician-monitored neurotherapy for brain health conditions including Alzheimer's, mood disorders, TBI, and PTSD. Provides remote patient monitoring, clinical data capture, EHR functionality, and analytics.
Quantifiable outcome
- 77.8% anxiety response rate at end of treatment, maintained at 8-week follow-up
- +4 more outcomes
Companies that use Nexalin Technology
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Nexalin Technology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Nexalin Technology partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and regional.
- GreenLight Ventures LLCcoreStrategic partnership following Nexalin's $1.3 million acquisition of PONM digital health platform. GreenLight Ventures became an equity holder in Nexalin and provides ongoing development services including engineering, regulatory, and commercial capabilities. The PONM platform supports HALO Clarity program and NeuroCare virtual clinic.
- Lindus HealthcoreAccountable Research Organization partnership for execution of pivotal FDA clinical trial for HALO Clarity insomnia treatment. Lindus Health providing full-scope trial execution from protocol finalization through database lock for the 160-participant randomized sham-controlled study.
- Professor Yi Tang, Xuanwu Hospital (China)regionalCollaboration with Professor Yi Tang from Xuanwu Hospital in China for Alzheimer's disease clinical program. Professor Tang brings extensive real-world clinical experience from ongoing studies using Nexalin's non-invasive neurostimulation device on Alzheimer's patients.
- University of California, San DiegocoreClinical research partnership for military TBI/PTSD study using HALO neurostimulation headset. PONM digital health platform deployed at UCSD supporting remote patient monitoring, clinical data capture, and virtual care workflows for the clinical trial program.
- Carmi Masha Technologies Ltd.regionalExclusive distribution agreement for marketing Gen-2 SYNC neurostimulation device in Israel following regulatory approval. Partnership aims to expand access to Nexalin's non-invasive mental health treatment and explore future applications in the Israeli market.
Scale indicators7 records
Recent moves6 records
Expansion highlights8 records
Nexalin Technology competitors and assessment
Company assessmentDirect peers
- Neuronetics: U.S.-listed developer of transcranial magnetic stimulation (NeuroStar) systems for major depressive disorder. Directly comparable to Nexalin because it competes in non-invasive neuromodulation for mental-health indications, including anxiety and depression, with similar provider-channel economics and FDA-cleared status.
- Brainsway: Israel-based developer of Deep TMS systems approved for depression, OCD, and smoking addiction. Highly comparable to Nexalin given its non-invasive neurostimulation modality, mental-health indications, and presence in Israel — the same market where Nexalin just received Gen-2 SYNC clearance.
- Electrocore: Developer of non-invasive vagus nerve stimulation (gammaCore) devices, primarily for migraine and headache but expanding into broader neurology. Comparable as a small-cap, non-invasive neurostimulation company pursuing adjacent neurological indications through a similar provider-channel model.
- NeuroPace: Developer of the RNS System, a closed-loop responsive neurostimulation device for refractory epilepsy. Comparable as a small-cap neurostimulation pure-play pursuing neurological indications, although NeuroPace is invasive/implanted whereas Nexalin is non-invasive.
Broad incumbents
- LivaNova: Larger diversified medical-device company with a Vagus Nerve Stimulation (VNS) Therapy system approved for drug-resistant epilepsy and treatment-resistant depression. Comparable as an established neuromodulation incumbent in mental-health indications, though it operates a broader device portfolio beyond neurostimulation.
- Axonics: Public neuromodulation company focused on sacral and pudendal nerve stimulation for incontinence and overactive bladder. Comparable as a small-to-mid-cap neurostimulation device company with FDA-cleared products, although its primary indications differ from Nexalin's CNS focus.
Emerging players
- Soterix Medical: Privately-held developer of transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) platforms for research and clinical applications. Closely comparable to Nexalin's DIFS technology on modality and waveform category, though Soterix is primarily research-focused and not a direct commercial competitor.
- Big Health: Digital therapeutics company commercializing Sleepio for insomnia and Daylight for anxiety. Comparable to the NeuroCare virtual-clinic / digital-therapeutic layer of Nexalin's offering — same indications (insomnia, anxiety), same digital-delivery model — although Big Health is software-only rather than device-anchored.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Nexalin Technology social profiles
Digital presenceNexalin Technology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nexalin Technology leadership team
Management profileNumber of profiles
Profiles6 records
Nexalin Technology subsidiaries and ownership
Company hierarchySubsidiaries1 record
Nexalin Technology funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nexalin Technology M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nexalin Technology
What does Nexalin Technology do?
Nexalin Technology develops and commercializes non-invasive transcranial neurostimulation devices based on its proprietary Deep Intracranial Frequency Stimulation (DIFS) platform, delivering 15 mA, 77.5 Hz frequency-based waveforms to treat anxiety, depression, insomnia, traumatic brain injury, PTSD, and Alzheimer's disease. The company sells its Gen-2 SYNC devices in approved international markets and operates an AI-powered NeuroCare virtual clinic platform that enables physicians to remotely prescribe and monitor home-based neurostimulation treatments.
Is Nexalin Technology a public or private company?
Nexalin Technology is a public company. It is classified as public and is currently operating.
When was Nexalin Technology founded?
Nexalin Technology was founded in 2010. It employs 1 to 10 people.
Where is Nexalin Technology based?
Nexalin Technology is headquartered in Houston, United States, in the North America region.
How does Nexalin Technology make money?
Three revenue lines are on record. Virtual Clinic Subscription is the primary driver. The others are device Sales and distribution/ Licensing.
Who are Nexalin Technology's main competitors?
Direct peers on record are Neuronetics, Brainsway, Electrocore and NeuroPace. Broad incumbents are LivaNova and Axonics. Emerging players are Soterix Medical and Big Health.
Does Nexalin Technology have an API?
No public API is recorded for Nexalin Technology.
What industry is Nexalin Technology in?
Nexalin Technology's product category is Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAA, General Neurology. Its NAICS code is 334510 and its SIC code is 3845.